Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 348,800 shares, a drop of 24.5% from the February 13th total of 462,200 shares. Currently, 1.4% of the shares of the company are short sold. Based on an average daily volume of 232,700 shares, the days-to-cover ratio is presently 1.5 days.

Wall Street Analyst Weigh In

Several equities research analysts have commented on GANX shares. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday. Roth Mkm restated a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, Scotiabank started coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Gain Therapeutics currently has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Price Performance

Shares of NASDAQ GANX traded down $0.02 during mid-day trading on Tuesday, reaching $2.38. 193,593 shares of the company traded hands, compared to its average volume of 278,390. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The firm has a market cap of $63.13 million, a PE ratio of -2.16 and a beta of 0.14. The stock has a fifty day simple moving average of $2.23 and a 200-day simple moving average of $2.01.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp increased its stake in shares of Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after acquiring an additional 44,750 shares during the period. Geode Capital Management LLC increased its stake in shares of Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares during the period. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics during the fourth quarter valued at approximately $35,000. Sprott Inc. acquired a new position in shares of Gain Therapeutics during the fourth quarter valued at approximately $30,000. Finally, Northern Trust Corp increased its stake in shares of Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.